Tecentriq 1 200 mg concentrate for solution for infusion
CSET N°2017/2608
Phase 2 small_molecule active
Quick answer
Tecentriq 1 200 mg concentrate for solution for infusion for Locally advanced cervical cancer is a Phase 2 program (small_molecule) at The George Institute with 1 ClinicalTrials.gov record(s).
Program details
- Company
- The George Institute
- Indication
- Locally advanced cervical cancer
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active